Leo Pharma goes head to head with Janssen in new psoriasis trial

Leo Pharma will test its psoriasis drug Kyntheum against Janssen's Tremfya, thereby also testing new-generation biologic treatments for psoriasis.

Photo: Leo Pharma / PR

In a new clinical trial, Danish pharmaceutical company Leo Pharma tries to get wind in the sails of the firm's first biologic treatment, Kyntheum.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs